These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11371266)

  • 21. Hormone therapy and hemostasis among postmenopausal women: a review.
    Canonico M
    Menopause; 2014 Jul; 21(7):753-62. PubMed ID: 24937030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential.
    Skouby S
    Acta Obstet Gynecol Scand; 2002 Sep; 81(9):793-8. PubMed ID: 12225293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guidelines for hormone treatment of women in the menopausal transition and beyond.
    Naftolin F; Schneider HP; Sturdee DW;
    Maturitas; 2005 May; 51(1):15-20. PubMed ID: 15883104
    [No Abstract]   [Full Text] [Related]  

  • 24. The history of hormone therapy use and recent controversy related to heart disease and breast cancer arising from prevention trial outcomes.
    Alexander IM
    J Midwifery Womens Health; 2012; 57(6):547-557. PubMed ID: 23217066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone therapy and breast cancer: the press-release version of WHI study data.
    Pines A
    Climacteric; 2013 Apr; 16(2):222-5. PubMed ID: 23488525
    [No Abstract]   [Full Text] [Related]  

  • 26. Understanding breast density and breast cancer risk.
    Peres J
    J Natl Cancer Inst; 2012 Sep; 104(18):1345-6. PubMed ID: 22984197
    [No Abstract]   [Full Text] [Related]  

  • 27. Postmenopausal estrogens--opposed, unopposed, or none of the above.
    Willett WC; Colditz G; Stampfer M
    JAMA; 2000 Jan; 283(4):534-5. PubMed ID: 10659883
    [No Abstract]   [Full Text] [Related]  

  • 28. Critical review of the article by Colditz et al. on 'The use of estrogens and progestins and the risk of breast cancer in postmenopausal women' published in the N.E.J.M. 1995, 332: 1589.
    Sismondi P; Biglia N
    Pharmacol Res; 1995 Dec; 32(6):329-30. PubMed ID: 8736482
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens.
    Scarabin PY; Hemker HC; Clément C; Soisson V; Alhenc-Gelas M
    Menopause; 2011 Aug; 18(8):873-9. PubMed ID: 21487317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen plus progestin, benefits and risks: the "Women's Health Initiative" trials.
    Keller KB; Lemberg L
    Am J Crit Care; 2005 Mar; 14(2):157-60. PubMed ID: 15728959
    [No Abstract]   [Full Text] [Related]  

  • 32. Re: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Archer DF; Bush T; Nachtigall LE
    J Natl Cancer Inst; 2000 Dec; 92(23):1950-2. PubMed ID: 11106695
    [No Abstract]   [Full Text] [Related]  

  • 33. Exogenous estrogen and urinary incontinence.
    Jackson SL; Fihn SD
    J Urol; 2009 May; 181(5):1989-91. PubMed ID: 19286197
    [No Abstract]   [Full Text] [Related]  

  • 34. The "red queen" and endometrial hyperplasia.
    Gambrell RD
    Fertil Steril; 1994 Feb; 61(2):401-2. PubMed ID: 8299806
    [No Abstract]   [Full Text] [Related]  

  • 35. Global consensus statement on menopausal hormone therapy.
    de Villiers TJ; Gass ML; Haines CJ; Hall JE; Lobo RA; Pierroz DD; Rees M
    Climacteric; 2013 Apr; 16(2):203-4. PubMed ID: 23488524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Landmark hormone replacement therapy study stopped after finding more harms than benefits.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):5-7. PubMed ID: 12553323
    [No Abstract]   [Full Text] [Related]  

  • 37. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of oestrogens and progestin and the risk of breast cancer in post-menopausal women. G.A. Colditz et al. N. Engl. J. Med. 1995; 332: 1589-93.
    Kauppila A
    Pharmacol Res; 1995 Dec; 32(6):327. PubMed ID: 8736481
    [No Abstract]   [Full Text] [Related]  

  • 39. Where are we with postmenopausal hormone therapy in 2005?
    Lam PM; Chung TK; Haines C
    Gynecol Endocrinol; 2005 Nov; 21(5):248-56. PubMed ID: 16373243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue Factor Pathway Inhibitor, Activated Protein C Resistance, and Risk of Coronary Heart Disease Due To Combined Estrogen Plus Progestin Therapy.
    Johnson KC; Aragaki AK; Jackson R; Reiner A; Sandset PM; Rosing J; Dahm AE; Rosendaal F; Manson JE; Martin LW; Liu S; Kuller LH; Cushman M; Rossouw JE
    Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):418-24. PubMed ID: 26681757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.